[{"id":"f452523a-9b0c-464f-bfe0-a10e5a2eac7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907527","created_at":"2021-01-18T19:14:09.446Z","updated_at":"2024-07-02T16:35:29.409Z","phase":"Phase 1","brief_title":"Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03907527","lead_sponsor":"Precigen, Inc","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRGN-3005"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 11/15/2028","study_completion_date":" 11/15/2028","last_update_posted":"2023-11-13"}]